Needham Remains Positive on Esperion Therapeutics (ESPR)

March 7, 2018 12:22 PM UTC Send to a Friend
Needham & Company maintains Strong Buy on Esperion Therapeutics (NASDAQ: ESPR) price target of $94.00.Analyst Chad Messer comments "The first ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login